Insulin Like Growth Factor Binding Protein-5 Regulates Excessive Vascular Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats Via ERK 1/2 Phosphorylation

Overview

Journal Korean J Physiol Pharmacol

Specialty Pharmacology

Date 2013 Apr 30

PMID 23626478

Citations 12

Authors

Dong Hyup Lee

Jung Eun Kim

Young Jin Kang

Affiliations

Soon will be listed here.

Abstract

Insulin-like growth factor binding proteins (IGFBPs) are important components of insulin growth factor (IGF) signaling pathways. One of the binding proteins, IGFBP-5, enhances the actions of IGF-1, which include the enhanced proliferation of smooth muscle cells. In the present study, we examined the expression and the biological effects of IGFBP-5 in vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY). The levels of IGFBP-5 mRNA and protein were found to be higher in the VSMC from SHR than in those from WKY. Treatment with recombinant IGFBP-5-stimulated VSMC proliferation in WKY to the levels observed in SHR. In the VSMCs of WKY, incubation with angiotensin (Ang) II or IGF-1 dose dependently increased IGFBP-5 protein levels. Transfection with IGFBP-5 siRNA reduced VSMC proliferation in SHR to the levels exhibited in WKY. In addition, recombinant IGFBP-5 significantly up-regulated ERK1/2 phosphorylation in the VSMCs of WKY as much as those of SHR. Concurrent treatment with the MEK1/2 inhibitors, PD98059 or U0126 completely inhibited recombinant IGFBP-5-induced VSMC proliferation in WKY, while concurrent treatment with the phosphatidylinositol-3 kinase inhibitor, LY294002, had no effect. Furthermore, knockdown with IGFBP-5 siRNA inhibited ERK1/2 phosphorylation in VSMC of SHR. These results suggest that IGFBP-5 plays a role in the regulation of VSMC proliferation via ERK1/2 MAPK signaling in hypertensive rats.

Citing Articles

Polyenylphosphatidylcholine alleviates cardiorenal fibrosis, injury and dysfunction in spontaneously hypertensive rats by regulating Plpp3 signaling.

Zhang Y, Ma J, Wei F, Gong J, Zhuang L, Zhang N Front Cardiovasc Med. 2024; 11:1458173.

PMID: 39403590 PMC: 11472324. DOI: 10.3389/fcvm.2024.1458173.

controls myogenesis by cis-modulation of in cattle.

Li X, Xing S, Meng S, Hou Z, Yu L, Chen M Epigenetics. 2024; 19(1):2341578.

PMID: 38615330 PMC: 11018032. DOI: 10.1080/15592294.2024.2341578.

Beyond the Rhythm: In Silico Identification of Key Genes and Therapeutic Targets in Atrial Fibrillation.

Atzemian N, Dovrolis N, Ragia G, Portokallidou K, Kolios G, Manolopoulos V Biomedicines. 2023; 11(10).

PMID: 37893006 PMC: 10604372. DOI: 10.3390/biomedicines11102632.

Integrated Omics analysis of pig muscle metabolism under the effects of dietary Chlorella vulgaris and exogenous enzymes.

Coelho D, Ribeiro D, Osorio H, de Almeida A, Mestre Prates J Sci Rep. 2022; 12(1):16992.

PMID: 36216870 PMC: 9551059. DOI: 10.1038/s41598-022-21466-z.

c-Kit expression in smooth muscle cells reduces atherosclerosis burden in hyperlipidemic mice.

Zigmond Z, Song L, Martinez L, Lassance-Soares R, Velazquez O, Vazquez-Padron R Atherosclerosis. 2021; 324:133-140.

PMID: 33781566 PMC: 8096668. DOI: 10.1016/j.atherosclerosis.2021.03.004.

References

Butt A, Dickson K, McDougall F, Baxter R . Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem. 2003; 278(32):29676-85. DOI: 10.1074/jbc.M301965200. View

Kim K, Seu Y, Baek S, Kim M, Kim K, Kim J . Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell. 2007; 18(11):4543-52. PMC: 2043568. DOI: 10.1091/mbc.e07-03-0280. View

Colao A, Spiezia S, Di Somma C, Pivonello R, Marzullo P, Rota F . Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest. 2005; 28(5):440-8. DOI: 10.1007/BF03347225. View

Hsieh T, Gordon R, Clemmons D, Busby Jr W, Duan C . Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins. J Biol Chem. 2003; 278(44):42886-92. DOI: 10.1074/jbc.M303835200. View

Wang J, Razuvaev A, Folkersen L, Hedin E, Roy J, Brismar K . The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis. 2011; 220(1):102-9. DOI: 10.1016/j.atherosclerosis.2011.10.032. View

Clemmons D . Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007; 6(10):821-33. DOI: 10.1038/nrd2359. View

Kuemmerle J, Zhou H . Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways. J Biol Chem. 2002; 277(23):20563-71. DOI: 10.1074/jbc.M200885200. View

Watanabe T, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T . Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens. 2003; 16(9 Pt 1):754-60. DOI: 10.1016/s0895-7061(03)00985-3. View

Resink T, Baur U, Buhler F . Increased proliferation fate and phosphoinositide turnover in cultured smooth muscle cells from spontaneously hypertensive rats. J Hypertens Suppl. 1987; 5(5):S145-8. View

10.

Vecchione C, Colella S, Fratta L, Gentile M, Selvetella G, Frati G . Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension. 2001; 37(6):1480-5. DOI: 10.1161/01.hyp.37.6.1480. View

11.

Delafontaine P, Song Y, Li Y . Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2003; 24(3):435-44. DOI: 10.1161/01.ATV.0000105902.89459.09. View

12.

Duan C . Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol. 2002; 175(1):41-54. DOI: 10.1677/joe.0.1750041. View

13.

Choi H, Lee K, Lee D, Kang Y . Heme oxygenase-1 induced by aprotinin inhibits vascular smooth muscle cell proliferation through cell cycle arrest in hypertensive rats. Korean J Physiol Pharmacol. 2009; 13(4):309-13. PMC: 2766711. DOI: 10.4196/kjpp.2009.13.4.309. View

14.

Salih D, Tripathi G, Holding C, Szestak T, Gonzalez M, Carter E . Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci U S A. 2004; 101(12):4314-9. PMC: 384738. DOI: 10.1073/pnas.0400230101. View

15.

Duan C, Liimatta M, Bottum O . Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. J Biol Chem. 1999; 274(52):37147-53. DOI: 10.1074/jbc.274.52.37147. View

16.

Bach L . The insulin-like growth factor system in kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2011; 21(1):86-91. DOI: 10.1097/MNH.0b013e32834dc1a2. View

17.

Zheng B, Clarke J, Busby W, Duan C, Clemmons D . Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology. 1998; 139(4):1708-14. DOI: 10.1210/endo.139.4.5945. View

18.

Schneider M, Wolf E, Hoeflich A, Lahm H . IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol. 2002; 172(3):423-40. DOI: 10.1677/joe.0.1720423. View

19.

Intengan H, Schiffrin E . Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001; 38(3 Pt 2):581-7. DOI: 10.1161/hy09t1.096249. View

20.

Duan C, Hawes S, Prevette T, Clemmons D . Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells. J Biol Chem. 1996; 271(8):4280-8. DOI: 10.1074/jbc.271.8.4280. View